Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report released on Tuesday morning, Benzinga reports. They currently have a $35.00 price target on the stock.

A number of other equities analysts have also recently commented on ATYR. Jefferies Financial Group started coverage on Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Atyr PHARMA in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company started coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They set an “overweight” rating and a $17.00 price target on the stock.

Atyr PHARMA Stock Performance

ATYR opened at $3.04 on Tuesday. Atyr PHARMA has a fifty-two week low of $1.08 and a fifty-two week high of $3.68. The company has a quick ratio of 7.63, a current ratio of 7.63 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $2.21. The firm has a market capitalization of $230.43 million, a P/E ratio of -3.34 and a beta of 1.21.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. On average, equities research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.